<DOC>
	<DOCNO>NCT02145923</DOCNO>
	<brief_summary>Subjects undergo peripheral blood stem cell mobilisation collection subsequent high-dose chemotherapy . After finalization high-dose chemotherapy subject receive bone marrow derive allogeneic multipotent mesenchymal stromal cell intravenous infusion two hour prior autologous peripheral blood cell infusion . This single arm study control . All patient receive cell therapy .</brief_summary>
	<brief_title>Effectiveness Safety MMSCs Enhancing Hematopoietic Recovery Prophylaxis Neutropenic Enterocolitis</brief_title>
	<detailed_description>Patients verify diagnosis Hodgkin 's lymphoma non-Hodgkin 's lymphoma undergo peripheral blood stem cell mobilisation collection ( chemotherapy + G-CSF G-CSF+Plerixafor ) . After high-dose chemotherapy perform accord protocol ICE BEAM ( standard scheme ) . Patient receive bone marrow derive allogeneic multipotent mesenchymal stromal cell infusion 48 hour last administration cytotoxic agent . Number cell calculate accord patient 's body weight ( 1,5-2,0 mln cells/kg ) , time infusion - 30 minute . Two hour later patient receive autologous peripheral blood cell infusion .</detailed_description>
	<mesh_term>Enterocolitis</mesh_term>
	<mesh_term>Enterocolitis , Neutropenic</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<criteria>Patient suffers Hodgkin 's lymphoma , nonHodgkin 's lymphoma complete partial remission . Patient candidate highdose chemotherapy subsequent autologous hematopoietic stem cell transplantation . Absence infection , cardiovascular , respiratory , renal hepatic dysfunction , focal neurological symptom . Karnofsky score least 70 . Patient successfully undergone mobilization peripheral blood stem cell . Patient familiar Participant information sheet . Patient sign informed consent form . Noninclusion Criteria : Severe chronic comorbidity symptom organ system failure . Significant abnormality laboratory test . Participation clinical trial ( intake study drug ) within prior 3 month . Conditions restrict commitment participate trial ( dementia , neuropsychiatric disorder , drug alcohol abuse ) Patients malignant solid tumor . Patients medical history heterotopic ossification . Progression relapse lymphoma therapy . Confirmed syphilis , HIV , hepatitis B C infection Absence clinical laboratory sign hematopoietic recovery persistent enterocolitis day 14 manipulation ( Visit 15 ) . While patient remain hospital continue treatment accord requirement standard therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Hodgkin Lymphoma</keyword>
	<keyword>Non-Hodgkin 's Lymphomas</keyword>
	<keyword>Allogeneic Mesenchymal Stem Cell Transplantation</keyword>
	<keyword>Autologous Peripheral Blood Stem Cell Transplantation</keyword>
	<keyword>Neutropenic Enterocolitis</keyword>
	<keyword>Myeloablative Chemotherapy</keyword>
	<keyword>Bone Marrow Aplasia</keyword>
</DOC>